内分泌系医薬品市場：治療領域別、流通チャネル別-2025-2030年の世界予測

内分泌系医薬品市場は、2023年に327億8,000万米ドルと評価され、2024年には350億5,000万米ドルに達すると予測され、CAGR 7.34％で成長し、2030年には538億5,000万米ドルに達すると予測されています。

内分泌系医薬品市場には、糖尿病、甲状腺疾患、ホルモンバランスの乱れなど、内分泌系に関連する疾患を治療するための医薬品が含まれます。内分泌系医薬品の必要性は、人口の高齢化、肥満率の上昇、ライフスタイルの変化といった要因に影響され、世界的にこれらの疾患の有病率が増加していることが背景にあります。これらの医薬品は、ホルモン補充療法、グルコース調節、代謝性疾患管理などに応用され、病院、診療所、個人患者などのエンドユーザーにサービスを提供しています。市場の成長は、バイオテクノロジーの進歩、個別化医療、革新的ドラッグデリバリーシステムの採用増加によって大きく牽引されています。新たな開発機会としては、特定のホルモン経路を標的とする新規化合物の開発や、デジタルヘルスソリューションによる患者のコンプライアンス強化などが挙げられます。しかし、市場は、高い研究開発費、厳しい規制の枠組み、ホルモン療法に伴う潜在的な副作用などの限界に直面しており、成長の妨げになる可能性があります。また、ジェネリック医薬品との競合や、コスト制約による発展途上地域での利用制限などの課題もあります。有望なイノベーション分野としては、非侵襲的デリバリーシステムの調査、バイオシミラーの最適化、精密医療に関する洞察のための人工知能の活用などが挙げられます。さらに、製薬企業と研究機関の協力により、ホルモン関連の病態における新たな発見が育まれる可能性があります。急速な技術進歩と進化するヘルスケア需要を特徴とするこの市場では、利害関係者は常に情報を入手し機敏に行動し、消費者と規制当局の両方のニーズに対応するための適応戦略を重視する必要があります。企業は、広く普及しているアンメット・クリニカル・ニーズに対応する研究段階への投資を優先し、製品化までの時間を短縮するために成分や技術のライセンシングに関する提携を模索すべきです。競合情勢は、戦略的M&Aの重要性を浮き彫りにしており、これによって企業は製品ポートフォリオと地域情勢を拡大することができます。結論として、臨床試験パイプラインと新たな規制を継続的に監視することが、内分泌系医薬品市場の機会を捉え課題を克服する上で極めて重要です。

市場力学：急速に進化する内分泌系医薬品市場の主要市場インサイトを公開

内分泌系医薬品市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 内分泌疾患の有病率の増加
  • 内分泌疾患とその管理に対する意識の高まり
  • 内分泌疾患の増加に寄与する高齢化人口の増加とライフスタイルの変化
• 市場抑制要因
  • 内分泌系医薬品の研究開発に伴う高コスト
• 市場機会
  • 個別化医療と標的療法への注目の高まり
  • 新規治療法開発のためのバイオテクノロジーの進歩
• 市場の課題
  • 医薬品承認のための厳しい規制要件

ポーターのファイブフォース：内分泌系医薬品市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：内分泌系医薬品市場における外部からの影響の把握

外部マクロ環境要因は、内分泌系医薬品市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析内分泌系医薬品市場における競合情勢の把握

内分泌系医薬品市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス内分泌系医薬品市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、内分泌系医薬品市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨内分泌系医薬品市場における成功への道筋を描く

内分泌系医薬品市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大の可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 内分泌疾患の罹患率の増加
    • 内分泌疾患とその管理に関する意識の高まり
    • 高齢化人口の増加とライフスタイルの変化が内分泌疾患の増加に寄与しています。
  • 抑制要因
    • 内分泌系医薬品の研究開発にかかるコストが高い
  • 機会
    • 個別化医療と標的療法への注目が高まる
    • 新たな治療法の開発に向けたバイオテクノロジーの進歩
  • 課題
    • 医薬品の承認に関する厳格な規制要件
• 市場セグメンテーション分析
  • 治療領域：世界中で糖尿病の罹患率が上昇し、内分泌系医薬品の研究開発が加速
  • 流通チャネル：自宅への配送の容易さからオンライン薬局の重要性が高まっている
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 内分泌系医薬品市場治療領域別

• 糖尿病治療薬
• ヒト成長ホルモン
• 甲状腺ホルモン障害

第7章 内分泌系医薬品市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第8章 南北アメリカの内分泌系医薬品市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の内分泌系医薬品市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの内分泌系医薬品市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • アレクシオン、アモリットファーマ買収で希少内分泌ポートフォリオを強化
  • イーライリリーのムンジャロ、インドで発売予定
  • ノボノルディスク、肥満・糖尿病治療ポートフォリオ拡大のためインバーサゴファーマを買収
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AbbVie Inc.
• Ascendis Pharma AS
• AstraZeneca PLC
• Bayer AG
• Beta Cell NV
• Biocon Limited
• Eli Lilly and Company
• Endo International PLC
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline PLC
• Hanmi Pharm Co., Ltd.
• Ipsen Pharma
• Johnson & Johnson Services, Inc.
• MacroGenics, Inc.
• MannKind Corporation
• Merck & Co., Inc.
• Novartis AG
• Novo Nordisk A/S
• Oramed Pharmaceuticals
• Pfizer Inc.
• Precigen, Inc.
• Sanofi S.A.
• Shenzhen Microchip Biotechnology Co., Ltd.
• Takeda Pharmaceutical Company Limited

LIST OF FIGURES

• FIGURE 1. ENDOCRINOLOGY DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. ENDOCRINOLOGY DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ENDOCRINOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. ENDOCRINOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ENDOCRINOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ENDOCRINOLOGY DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DIABETES DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HUMAN GROWTH HORMONE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THYROID HORMONE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 18. ARGENTINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 19. ARGENTINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 20. BRAZIL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 21. BRAZIL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 22. CANADA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 23. CANADA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 24. MEXICO ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 25. MEXICO ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 28. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. AUSTRALIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 33. AUSTRALIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 34. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 35. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36. INDIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 37. INDIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 38. INDONESIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 39. INDONESIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. JAPAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 41. JAPAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. MALAYSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 43. MALAYSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. PHILIPPINES ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 45. PHILIPPINES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. SINGAPORE ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 47. SINGAPORE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 48. SOUTH KOREA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 49. SOUTH KOREA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 50. TAIWAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 51. TAIWAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. THAILAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 53. THAILAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. VIETNAM ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 55. VIETNAM ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 59. DENMARK ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 60. DENMARK ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. EGYPT ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 62. EGYPT ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 63. FINLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 64. FINLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. FRANCE ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 66. FRANCE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. GERMANY ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 68. GERMANY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 69. ISRAEL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 70. ISRAEL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. ITALY ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 72. ITALY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. NETHERLANDS ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 74. NETHERLANDS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. NIGERIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 76. NIGERIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. NORWAY ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 78. NORWAY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. POLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 80. POLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 81. QATAR ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 82. QATAR ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. RUSSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 84. RUSSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. SAUDI ARABIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 86. SAUDI ARABIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. SPAIN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 90. SPAIN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. SWEDEN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 92. SWEDEN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 93. SWITZERLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 94. SWITZERLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. TURKEY ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 96. TURKEY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. UNITED ARAB EMIRATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 98. UNITED ARAB EMIRATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 99. UNITED KINGDOM ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 100. UNITED KINGDOM ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. ENDOCRINOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 102. ENDOCRINOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Endocrinology Drugs Market was valued at USD 32.78 billion in 2023, expected to reach USD 35.05 billion in 2024, and is projected to grow at a CAGR of 7.34%, to USD 53.85 billion by 2030.

The endocrinology drugs market encompasses pharmaceuticals designed to treat disorders related to the endocrine system, including diabetes, thyroid diseases, and hormonal imbalances. The necessity for endocrinology drugs is driven by the increasing prevalence of these conditions globally, influenced by factors such as aging populations, rising obesity rates, and lifestyle changes. These drugs are applied in hormone replacement therapies, glucose regulation, and metabolic disease management, serving end-users like hospitals, clinics, and individual patients. Market growth is significantly driven by advancements in biotechnology, personalized medicine, and the increasing adoption of innovative drug delivery systems. Emerging opportunities include the development of novel compounds targeting specific hormone pathways and enhancing patient compliance through digital health solutions. However, the market faces limitations such as high R&D costs, stringent regulatory frameworks, and potential side effects associated with hormonal therapies that may hinder growth. Challenges also include competition from generic drugs and limited accessibility in developing regions due to cost constraints. Innovation areas with promising potential include researching non-invasive delivery systems, optimizing biosimilars, and leveraging artificial intelligence for precision medicine insights. Moreover, collaborations between pharmaceutical companies and research institutions can foster new discoveries in hormone-related pathologies. The market, characterized by rapid technological advancements and evolving healthcare demands, requires stakeholders to stay informed and agile, emphasizing adaptive strategies to address both consumer and regulatory needs. Companies should prioritize investment in research phases that address prevalent unmet clinical needs and explore partnerships for ingredient or technology licensing to expedite time-to-market. The competitive landscape underscores the importance of strategic mergers and acquisitions, enabling firms to expand product portfolios and geographic reach. In conclusion, continuous monitoring of clinical trial pipelines and emerging regulations will be crucial for seizing opportunities and navigating challenges in the endocrinology drugs market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Endocrinology Drugs Market

The Endocrinology Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of endocrine disorders
  • Growing awareness about endocrine disorders and their management
  • Growing aging population and lifestyle changes contributing to the rise in endocrine disorders.
• Market Restraints
  • High cost associated with research and development of endocrinology drugs
• Market Opportunities
  • Increasing focus on personalized medicine and targeted therapies
  • Advancements in biotechnology for the development of novel therapeutic options
• Market Challenges
  • Stringent regulatory requirements for drug approval

Porter's Five Forces: A Strategic Tool for Navigating the Endocrinology Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Endocrinology Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Endocrinology Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Endocrinology Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Endocrinology Drugs Market

A detailed market share analysis in the Endocrinology Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Endocrinology Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Endocrinology Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Endocrinology Drugs Market

A strategic analysis of the Endocrinology Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Endocrinology Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Ascendis Pharma AS, AstraZeneca PLC, Bayer AG, Beta Cell NV, Biocon Limited, Eli Lilly and Company, Endo International PLC, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Hanmi Pharm Co., Ltd., Ipsen Pharma, Johnson & Johnson Services, Inc., MacroGenics, Inc., MannKind Corporation, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals, Pfizer Inc., Precigen, Inc., Sanofi S.A., Shenzhen Microchip Biotechnology Co., Ltd., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Endocrinology Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Therapy Area, market is studied across Diabetes Drugs, Human Growth Hormone, and Thyroid Hormone Disorders.
• Based on Distribution Channel, market is studied across Hospital pharmacies, Online pharmacies, and Retail pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of endocrine disorders
    • 5.1.1.2. Growing awareness about endocrine disorders and their management
    • 5.1.1.3. Growing aging population and lifestyle changes contributing to the rise in endocrine disorders.
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with research and development of endocrinology drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing focus on personalized medicine and targeted therapies
    • 5.1.3.2. Advancements in biotechnology for the development of novel therapeutic options
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory requirements for drug approval
• 5.2. Market Segmentation Analysis
  • 5.2.1. Therapy Area: Growing prevalence of diabetes across the globe accelerating research & development of endocrinology drugs
  • 5.2.2. Distribution Channel: Increasing significance of online pharmacies due to ease of home delivery
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Endocrinology Drugs Market, by Therapy Area

• 6.1. Introduction
• 6.2. Diabetes Drugs
• 6.3. Human Growth Hormone
• 6.4. Thyroid Hormone Disorders

7. Endocrinology Drugs Market, by Distribution Channel

• 7.1. Introduction
• 7.2. Hospital pharmacies
• 7.3. Online pharmacies
• 7.4. Retail pharmacies

8. Americas Endocrinology Drugs Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Endocrinology Drugs Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Endocrinology Drugs Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. Alexion to Bolster Rare Endocrinology Portfolio with Amolyt Pharma Acquisition
  • 11.3.2. Anticipated Launch of Eli Lilly's Mounjaro in India
  • 11.3.3. Novo Nordisk Acquires Inversago Pharma to Expand Obesity and Diabetes Treatment Portfolio
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. Ascendis Pharma AS
• 4. AstraZeneca PLC
• 5. Bayer AG
• 6. Beta Cell NV
• 7. Biocon Limited
• 8. Eli Lilly and Company
• 9. Endo International PLC
• 10. F. Hoffmann-La Roche Ltd.
• 11. GlaxoSmithKline PLC
• 12. Hanmi Pharm Co., Ltd.
• 13. Ipsen Pharma
• 14. Johnson & Johnson Services, Inc.
• 15. MacroGenics, Inc.
• 16. MannKind Corporation
• 17. Merck & Co., Inc.
• 18. Novartis AG
• 19. Novo Nordisk A/S
• 20. Oramed Pharmaceuticals
• 21. Pfizer Inc.
• 22. Precigen, Inc.
• 23. Sanofi S.A.
• 24. Shenzhen Microchip Biotechnology Co., Ltd.
• 25. Takeda Pharmaceutical Company Limited